Log In
Print
BCIQ
Print
Print this Print this
 

Obizur (OBI-1)

  Manage Alerts
Collapse Summary General Information
Company Baxter International Inc.
DescriptionRecombinant porcine Factor VIII
Molecular Target Factor VIII
Mechanism of Action 
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentApproved
Standard IndicationHemophilia
Indication DetailsTreat acquired hemophilia; Treat acquired hemophilia A; Treat acquired hemophilia A in patients who have developed inhibitory antibodies to human Factor VIII; Treat congenital hemophilia A; Treat hemophilia A; Treat hemophilia A patients refractory to human Factor VIII treatment
Regulatory Designation

U.S. - Fast Track (Treat acquired hemophilia A);
EU - Orphan Drug (Treat acquired hemophilia)

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today